Dados B3 › UGPA3 × PETR4
UGPA3 × PETR4
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | UGPA3 | PETR4 | year |
|---|---|---|---|
| ROE | 15.9% | 28.2% | 2025 |
| ROIC | 12.1% | 14.8% | 2025 |
| ROA | 5.7% | 9.4% | 2025 |
| Gross margin | 6.6% | 47.6% | 2025 |
| EBIT margin | 3.5% | 29.3% | 2025 |
| Net margin | 1.8% | 22.2% | 2025 |
| Net debt/EBITDA | 2.26x | 1.45x | 2025 |
| Current ratio | 1.62x | 0.71x | 2025 |
| Revenue growth (1y) | 6.6% | 1.4% | 2025 |
| Revenue growth (5y CAGR) | 14.0% | 12.8% | 2025 |
| Piotroski F-Score | 4/9 | 7/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | UGPA3 | PETR4 | year |
|---|---|---|---|
| P/E | 11.46x | 4.76x | 2025 |
| P/B | 1.79x | 1.26x | 2025 |
| EV/EBITDA | 6.54x | 3.73x | 2025 |
| FCF yield | 12.3% | 17.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 14:20 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.